Brussels (Belgium), 28 October 2015 – 7:00 (CET) – regulated information –
UCB Interim Report for the first 9 months of 2015:
Revenue up 19%* to € 2 864 million, +12% CER1.
Cimzia®, Vimpat® and Neupro® combined net sales of € 1 469 million, +41% or +24% CER1. Keppra® net sales of € 565 million (+12%; +2% CER1)
R&D update: Phase 3 in EU for Vimpat® as monotherapy with positive results; U.S. Phase 3 for Cimzia® in non-radiographic axial spondyloarthritis started; bimekizumab with positive topline results in psoriatic arthritis
Financial outlook 2015 updated: Revenue expected at approximately € 3.75 billion, rEBITDA now expected about € 800 million, Core EPS in the range of € 2.00-2.10
lees meer op
http://www.ucb.com/presscenter/News/article/Strong-growth-of-core-medicines-continued-growth-of-the-pipeline

Het volledige bericht was niet over te nemen.